Substance, composition, or device? EPO addresses method of reaching a decision

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Substance, composition, or device? EPO addresses method of reaching a decision

Sponsored by

inspicos-400px recrop.jpg
Patent Health Care Pharmaceuticals Innovation concept. Copy rights patented certified medicine.

While concrete definitions are still lacking, Peter Koefoed of Inspicos says patent applicants seeking protection for second medical uses of products could now find it easier to build their case

Under Article 53(c) of the European Patent Convention (EPC), methods of therapy or surgery for humans and animals are exempted from patentability, as are diagnostic methods carried out on the human or animal body. At the same time, Article 53(c) specifies that this exemption does not apply to products – in particular, substances and compositions – for use in these methods.

Moreover, Article 54(5), by legal fiction, acknowledges novelty of any "substance or composition" for use in such exempted methods that are themselves novel. It can be derived from the wording of the latter provisions that they only apply to a subset of the products mentioned in Article53(c): substances and compositions.

Board of appeal case law has previously sought to establish criteria for determining whether a product is a substance or composition and not a device. These criteria are laid down in the Guidelines for Examination, G-VI, 6.1.1, which states that a product qualifies as a substance or composition if it is the active agent or ingredient in the specific medical use and if the therapeutic effect can be ascribed to its chemical properties (see G 5/83 and T 1758/15).

In decision T 1252/20 (relating to peptides used in cancer treatment by mechanically blocking blood vessels), of February 6 2024, the board saw no basis in the EPC for considering the mode of action of the claimed substance or composition to determine compliance with Article 54(5). The board pointed out that the exempted methods in Article 53(c) are not merely medical methods but also surgery and diagnostic methods. Moreover, the precise mode of action of a product is not always known. The board hence concluded that it is only relevant to consider whether the claimed product is a substance or composition but not to consider its mode of action.

T 1252/20 does not offer a concrete definition of a substance or composition. Nevertheless, applicants may face fewer obstacles when seeking protection at the EPO for second medical uses of products in cases where the claimed product at face value does not have device-like features.

more from across site and SHARED ros bottom lb

More from across our site

Justin Hill and Marie Jansson Heeks, part of an 18-strong team to have joined Crowell & Moring, explain why IP client advice must go beyond only being called upon for patent disclosure
To mark the EUIPO having processed five million EUTM and REUD applications, Managing IP speaks to the most prolific representatives to uncover how they stay at the top of their game
The merger marks Rouse’s second M&A deal within a month, and will provide access to Arnold & Siedsma’s UPC offering
Simon Tønners explains why IP provides the chance to work with some of the most passionate, risk-taking, and emotionally invested clients
The co-leaders of the firm’s new SEP practice group say the team will combine litigation and prosecution expertise to guide clients through cross-border challenges
Boasting four former Spruson & Ferguson leaders and with offices in Hong Kong and Singapore, the IP firm aims to provide fast, practical advice to clients
Partners at three law firms explain why trade secrets cases are rising, and how litigation is giving clients a market advantage
Delegates at a conference unpicking the UK’s relationship with the UPC are hopeful of strengthened UK involvement – so should we all be
News of a litigation funder suing its co-founder and a law firm over trade secrets infringement, and a strategic hire by Womble Bond Dickinson were also among the top talking points
Managing IP’s parent company, LBG, will acquire The Lawyer, a leading news, intelligence, and data-driven insight provider for the legal industry, from Centaur Media
Gift this article